Evotec ROCE 2026 | DE0005664809 | EVT.DE

In 2026, Evotec's return on capital employed (ROCE) was -0.08, a 118.34% increase from the -0.04 ROCE in the previous year.

Evotec Aktienanalyse

What does Evotec do? Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Evotec's Return on Capital Employed (ROCE)

Evotec's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Evotec's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Evotec's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Evotec’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Evotec stock

What is the ROCE (Return on Capital Employed) of Evotec this year?

The ROCE of Evotec is -0.08 undefined this year.

How has the ROCE (Return on Capital Employed) of Evotec developed compared to the previous year?

The ROCE of Evotec has increased by 118.34% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Evotec?

A high Return on Capital Employed (ROCE) indicates that Evotec has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Evotec?

A low ROCE (Return on Capital Employed) can indicate that Evotec has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Evotec impact the company?

An increase in the ROCE of Evotec can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Evotec affect the company?

A decrease in ROCE of Evotec can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Evotec?

Some factors that can affect Evotec's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Evotec so important for investors?

The ROCE of Evotec is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Evotec take to improve the ROCE?

To improve the ROCE, Evotec can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Evotec pay?

Over the past 12 months, Evotec paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evotec is expected to pay a dividend of 0 EUR.

What is the dividend yield of Evotec?

The current dividend yield of Evotec is .

When does Evotec pay dividends?

Evotec pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Evotec?

Evotec paid dividends every year for the past 0 years.

What is the dividend of Evotec?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Evotec located?

Evotec is assigned to the 'Health' sector.

Wann musste ich die Aktien von Evotec kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Evotec from amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on .

When did Evotec pay the last dividend?

The last dividend was paid out on .

What was the dividend of Evotec in the year 2025?

In the year 2025, Evotec distributed 0 EUR as dividends.

In which currency does Evotec pay out the dividend?

The dividends of Evotec are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Evotec stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Evotec

Our stock analysis for Evotec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evotec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.